No quarterly revenue total was found in TRANSCODE THERAPEUTICS, INC.'s SEC filings.
Transcode Therapeutics, Inc. (RNAZ) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-6.75M
-57.8% vs year-ago quarter
Operating cash flow
$-5.40M
-28.8% vs year-ago quarter
Free cash flow
$-8.16M
-107.8% vs prior quarter
EPS
$-7.17
-39.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
16.93M
+1930.8% vs year-ago quarter
Net cash
$5.77M
Q4 FY2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNAZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829635
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.8M | -$17.8M | -$16.0M | -$4.6M | -$4.2M |
| Net income | -$6.8M | -$17.8M | -$13.4M | -$4.9M | -$4.3M |
| Diluted EPS | -$7.17 | -$21.28 | -$16.55 | -$5.82 | -$5.13 |
| Operating cash flow | -$5.4M | -$5.0M | -$8.1M | -$4.1M | -$4.2M |
| Free cash flow | — | — | -$8.2M | — | — |
| Total assets | $151.0M | $157.2M | $162.4M | $5.2M | $8.3M |
| Total liabilities | $12.7M | $12.6M | $10.5M | $3.8M | $2.1M |
| Stockholders' equity | -$27.7M | $1.3M | $10.3M | $1.4M | $6.1M |
| Cash and investments | $8.4M | $12.8M | $17.8M | $2.8M | $7.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Aug 3, 2026 | Aug 3, 2026 |
All 324 Transcode Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.